Industry News Summit Therapeutics / Akeso BioSpace
FDA rejects Summit's ivonescimab in EGFR-mutated lung cancer, citing missing survival benefit
- FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, which would have been the first US approval of a PD-1xVEGF bispecific.
- The agency said progression-free survival gains without a statistically significant overall survival benefit do not show a positive benefit-risk profile; HARMONi missed its OS endpoint, and Summit's September follow-up analysis did not change that.
- Summit says it will keep building evidence across several NSCLC settings and gave no next step for this indication; partner Akeso already markets the drug in China.
The rejection was widely expected, and the lesson is about trial design: a PFS-only win in a post-TKI setting will not clear today's FDA. The bigger pivot is the Western first-line HARMONi-3 readout, which now carries the whole US thesis, and the combination partners lined up with Summit (AstraZeneca, Pfizer, Revolution Medicines) are holding options, not commitments.
Source: BioSpace ↗ Summit's PD-1xVEGF rejected by FDA in lung cancer